Revance Reports Positive 24-week Results For Injectable RT002; Stock Jumps

(RTTNews) - Revance Therapeutics, Inc. (RVNC), announced positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The company noted that the topline interim data showed that RT002, a botulinum toxin type A investigational drug product candidate for injection, achieved its primary efficacy measurement for all three doses at 4 weeks. RT002 appeared to be generally safe and well-tolerated across all cohorts.

The company's stock gained 54 percent to $41.27 in the pre-market trading based on the news.

Revance specified that the ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy and duration of effect of three doses of RT002 against placebo, and BOTOX Cosmetic/ VISTABEL.

Dan Browne, President and Chief Executive Officer at Revance, said, "The results clearly support that 40U is the right dose to take forward. We plan to report BELMONT's final study results and to conduct an End-of-Phase 2 meeting with the FDA in the first half of next year. We expect to begin Phase 3 clinical studies in the second half of 2016,"